| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5814639 | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Sep, 2015
(8 years ago) | |
| US5914331 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jul, 2017
(6 years ago) | |
| US5935946 | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jul, 2017
(6 years ago) | |
| US5977089 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
| US5922695 | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jul, 2017
(6 years ago) | |
| US7067522 | GILEAD SCIENCES INC | 2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents |
Dec, 2019
(4 years ago) | |
| US6838464 | GILEAD SCIENCES INC | 2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents |
Feb, 2021
(3 years ago) | |
| US6703396 | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Mar, 2021
(3 years ago) | |
| US8080551 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(1 year, 9 days ago) | |
| US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(1 year, 1 day from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5814639 (Pediatric) | GILEAD SCIENCES INC | Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds |
Mar, 2016
(8 years ago) | |
| US6043230 | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jul, 2017
(6 years ago) | |
|
US5914331 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Jan, 2018
(6 years ago) | |
|
US6043230 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US5935946 (Pediatric) | GILEAD SCIENCES INC | Nucleotide analog composition and synthesis method |
Jan, 2018
(6 years ago) | |
|
US5977089 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethoxy nucleotide analogs having increased oral bioavailability |
Jan, 2018
(6 years ago) | |
|
US5922695 (Pediatric) | GILEAD SCIENCES INC | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
Jan, 2018
(6 years ago) | |
| US6642245 | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
Nov, 2020
(3 years ago) | |
|
US6642245 (Pediatric) | GILEAD SCIENCES INC | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
May, 2021
(2 years ago) | |
|
US6703396 (Pediatric) | GILEAD SCIENCES INC | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
Sep, 2021
(2 years ago) | |
| US8101629 | GILEAD SCIENCES INC | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(1 year, 8 months ago) | |
| US9457036 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8716264 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US8592397 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
| US9744181 | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jan, 2024
(3 months ago) | |
|
US8716264 (Pediatric) | GILEAD SCIENCES INC | Compositions and methods for combination antiviral therapy |
Jul, 2024
(2 months from now) | |
| US8841310 | GILEAD SCIENCES INC | Combinations of a pyrimidine containing NNRTI with RT inhibitors |
Dec, 2025
(1 year, 7 months from now) | |
| US10857102 | GILEAD SCIENCES INC | Therapeutic compositions comprising rilpivirine HCL and tenofovir disoproxil fumarate |
Jan, 2033
(8 years from now) | |
Complera is owned by Gilead Sciences Inc.
Complera contains Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Disoproxil Fumarate.
Complera has a total of 28 drug patents out of which 24 drug patents have expired.
Expired drug patents of Complera are:
- US5814639*PED
- US6043230
- US5914331*PED
- US6043230*PED
- US5935946*PED
- US5977089*PED
- US5922695*PED
- US6642245
- US6642245*PED
- US6703396*PED
- US8101629
- US9457036
- US8716264
- US8592397
- US9744181
- US5814639
- US5914331
- US5935946
- US5977089
- US5922695
- US7067522
- US6838464
- US6703396
- US8080551
Complera was authorised for market use on 10 August, 2011.
Complera is available in tablet;oral dosage forms.
Complera can be used as treatment of hiv infection.
Drug patent challenges can be filed against Complera from 21 May, 2015.
The generics of Complera are possible to be released after 14 January, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 13, 2016 |
| New Chemical Entity Exclusivity(NCE) | May 20, 2016 |
NCE-1 date: 21 May, 2015
Market Authorisation Date: 10 August, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL
COMPLERA family patents
